Abstract
: The diversity of the portfolio of pharmaceutical and non-pharmacological services is an undeniable necessity; however, we must remember that the thinking of harm reduction should govern this process. If we only pay attention to the variety of drugs and their different forms, eventually the noble goal of harm reduction will suffer. In an article that Pedersen et al. prepared about the slow-release form of buprenorphine, there are structural and content problems that will be addressed in this article. This article criticizes the rapid change in the provision of harm reduction services and discusses the impact of structural changes in the provision of services and the location of service provision.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
